ZIVO Zivo Bioscience, Inc.

Overview and Growth

Fiscal 2024 results for Zivo Bioscience, Inc. combined $157.22K of revenue with net loss of $13.38M and an operating cash outflow of $4.31M. The $157.22K revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line expanded 468.6% from $27.65K in fiscal 2023, increasing the company’s operating scale. Diluted earnings per share were -$4.23, translating the period’s attributable earnings into the amount reported for each diluted share. Diluted shares averaged 3.17M; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 87.4% from 1.69M in fiscal 2023, leaving the current share base higher year over year. The company employed $1.64M of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.1x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

The first profit layer was $48.95K of gross profit, the amount available after reported direct revenue costs to absorb operating expenses. Gross margin was 31.1%, so that share of each revenue unit remained after the cost of revenue reported for the period. Operations produced a $13.36M operating loss before non-operating and tax effects. After all below-operating-line items, the company recorded a net loss of $13.38M for the fiscal year. The loss-to-assets relationship was 814.6%, placing the bottom-line deficit against the company’s resource base. Compared with a $7.78M net loss in fiscal 2023, the current loss increased to $13.38M.

Liquidity and Capital Structure

Total assets were $1.64M, supported by $2.16M of liabilities and -$514.90K of shareholder equity. With total equity at -$514.90K, the company carried a negative book-capital position, increasing its reliance on liabilities and future earnings. Current assets were $1.64M against $2.04M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 0.8x, current liabilities exceeded current assets and placed pressure on the company’s near-term liquidity position. Cash and equivalents totaled $1.54M, identifying the most liquid reported component available within the broader current-asset balance. The cash balance equaled 75.5% of current liabilities, showing how much near-term coverage came from cash alone. Equity equaled -31.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 131.3%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 93.9%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 195.7% from $555.72K in fiscal 2023, leaving current total assets higher year over year. Compared with $274.38K in fiscal 2023, the current cash balance moved 462.2% and finished higher.

Cash Flow and Earnings Quality

Operating activities used $4.31M of cash, resulting in an operating cash outflow for the year. Compared with a $5.80M operating cash outflow in fiscal 2023, the current outflow improved to $4.31M.

Based on the annual report for the fiscal year ending Dec 31, 2024. Analysis generated Oct 21, 2026.